396-02-1

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-7-(trifluoromethyl)quinazoline is used as a chemical intermediate for the synthesis of various biologically active molecules. Its unique molecular structure allows it to be a valuable component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agricultural Industry:
In the agricultural sector, 2,4-Dichloro-7-(trifluoromethyl)quinazoline is utilized as a herbicide, specifically for controlling broadleaf weeds in a range of crops. Its effectiveness in managing unwanted plant growth helps to protect and enhance crop yields, ensuring agricultural productivity.
Safety Note:
Given the potential toxic effects of 2,4-Dichloro-7-(trifluoromethyl)quinazoline, it is crucial to follow proper handling and safety precautions when working with 2,4-Dichloro-7-(trifluoromethyl)quinazoline in both research and application settings. This ensures the well-being of individuals and the environment.

InChI:InChI=1/C9H3Cl2F3N2/c10-7-5-2-1-4(9(12,13)14)3-6(5)15-8(11)16-7/h1-3H

Upstream product

• 402-13-1 2-amino-4-trifluoromethylbenzoic acid 
• 57-13-6 urea 
• 10026-13-8 phosphorus pentachloride 
• 3833-78-1 7-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione 
• 10025-87-3 trichlorophosphate 
• 3833-78-1 7-trifluoromethyl-quinazoline-2,4-diol 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 
• 778-94-9 2-nitro-4-trifluoromethyl-benzonitrile 

Downstream Products

• 159870-93-6 2-chloro-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-86-5 2-[(1R,2R)-2-(dimethylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-87-6 2-[(1R,2R)-2-(diethylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-88-7 2-[(1R,2R)-2-(dipropylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-89-8 2-[(1R,2R)-2-(piperidin-1-yl)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-90-1 2-[(1R,2R)-2-(isopropylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-93-4 2-[(1S,2S)-2-(dimethylamino)-1,2-diphenylethylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-94-5 2-[(1S,2S)-2-amino-1,2-diphenylethylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379686-21-1 CHF₃O₃S*C₁₇H₁₄F₃N₃O 
• 1388043-95-5 2-chloro-7-(trifluoromethyl)quinazoline 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments

Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 50 50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

AMIDO COMPOUNDS AS AhR MODULATORS

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

A catalyst-free N-H insertion/Mannich-type reaction cascade of α-nitrodiazoesters

A catalyst-free N-H insertion/Mannich-type reaction cascade of α-nitrodiazoesters with anilines has been developed to afford a variety of α-amino-α-aryl esters in 60-83% yields and under mild reaction conditions (23 or 40 C).

Design and development of bioinspired guanine-based organic catalyst for asymmetric catalysis

Design, preparation, and studies of a family of new organic catalysts are presented. The design of the catalysts is inspired by the ability of DNA nucleobases to develop precise and explicit hydrogen bonds. We have shown that this phenomenon can be used to create a useful organic catalyst that demonstrates a recognition pattern similar to those of common organic substrates. A selected bifunctional catalyst based on a guanine structure has been shown to catalyze the conjugate addition of 1,3-dicarbonyl compounds to various nitroalkenes, providing the products in good yields and enantioselectivities.

AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

Tricyclic dicarbonyl derivatives

Compounds of general formula (Ia), (Ib) and (II), wherein R1 and R2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R3 R4 NS(O)2 -- and R3 and R4 signify lower alkyl, and R2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH2 NHCH3, a bicyclic heterocycle with 1-3N atoms or a group --NR5 R6 or --OR5 in which R5 and R6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH=CH--, --CH=N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.